Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Alvotech Begins Confirmatory Study On EYLEA® Biosimilar

    Last week Alvotech announced that it has initiated a confirmatory study for its biosimilar candidate to EYLEA®, AVT06 (aflibercept). EYLEA® is indicated for treating a variety of eye disorders...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech Initiates Study Of Biosimilar Of J&J's Rheumatoid Arthritis Drug SIMPONI

    Alvotech announced yesterday the initiation of a pharmacokinetic study for AVT05, a biosimilar referencing Johnson & Johnson's ("J&J") SIMPONI and SIMPONI ARIA (golimumab).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
Article

Amgen Launches Its Aflibercept Biosimilar In The U.S.

After the Federal Circuit's denial last month of Regeneron's motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar...
United StatesFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP
  • Article

    Amneal Launches FYLNETRA (pegfilgrastim-pbbk) In The United States

    Last week, Amneal announced the launch of FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA, in the United States.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Another Exciting Nano Biotechnology Development – From IBM

    A summary of the most recent published research from IBM and others on nanoscale magnetic resonance imaging.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar

    On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's proposed biosimilar to EYLEA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    BioNTech Announces Transaction To Acquire CureVac

    On June 12, 2025, BioNTech SE ("BioNTech") announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. ("CureVac"), with an implied aggregate equity value for CureVac of approximately $1.25 billion.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Biosimilar Clinical Trial Updates

    On May 4, 2023, Alvotech announced the initiation of a confirmatory patient study for AVT05, a biosimilar candidate to Simponi and Simponi Aria.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Biosimilar Deals Updates: Biocon, AstraZeneca

    As an update to our previous report, Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) announced the successful completion of the transition of the acquired biosimilars...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Biosimilars Pathway Enacted

    On December 24, 2009, the U.S. Senate passed the Patient Protection and Affordable Care Act (H.R. 3590), its version of comprehensive healthcare reform legislation.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley Hoag LLP
    Foley Hoag LLP
  • Podcast

    Bloomberg Intelligence – Arman Oruc's Perspective On The FTC And Pharma And Biotech Industry M&A Impact (Podcast)

    Arman Oruc joined the Bloomberg Intelligence podcast to share his views on the FTC, and its impact on M&A for the pharma and biotech industry.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Blumberg Institute Hosts ‘Entrepreneur Spotlight' For Business, Biotech Leaders

    Loren D. Danzis, Jeffrey H. Nicholas and Elizabeth D. Sigety were featured in the Pennsylvania Business Daily article, "Blumberg Institute Hosts ‘Entrepreneur Spotlight' for Business, Biotech Leaders."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fox Rothschild LLP
    Fox Rothschild LLP
  • Article

    Book 16 Meetings With Life Science Investors One Day At RESI

    This one-day conference provides the highest ROI in the industry by bringing together innovative technology and active early stage investors looking to deploy capital.
    United StatesFood, Drugs, Healthcare, Life Sciences
    McGuireWoods LLP
    McGuireWoods LLP
  • Article

    CAFC Holds ITC Must Grant Relief Against Defaulting Respondents Under 19 U.S.C. § 1337(G)(1) In Laerdal Medical Corp. v. ITC

    In Laerdal Medical Corp. v. International Trade Commission, No. 17-2445, the CAFC reversed the ITC's final determination that Laerdal failed to plead its trade dress infringement claims with adequate detail...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Cancer Never Cares About Anything Like That

    Cayla Page contributed an article to the Newsletter of the Patient and Family Advisory Program at Moffitt Cancer Center titled "Cancer Never Cares About Anything Like That."
    United StatesFood, Drugs, Healthcare, Life Sciences
    Greenberg Traurig
    Greenberg Traurig
  • Article

    CDER, CDRH Discuss Efforts To Promote Medical Innovation At House Roundtable

    FDA program directors urged legislators to advance policies that will ease market entry for innovative pharmaceuticals and medical devices.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    CDRH Releases 2014–2015 Strategic Priorities Report

    In early February, the Center for Devices and Radiological Health released its 2014–2015 Strategic Priorities.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Celltrion's Bevacizumab Biosimilar Approved By FDA

    Celltrion announced this week that the FDA has approved VEGZELMA (bevacizumab-adcd), a biosimilar to AVASTIN, for treatment of six types of cancer...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Celltrion Files Second Biosimilar Patent Lawsuit

    Celltrion Healthcare became the second company developing a biosimilar to file a declaratory judgment action before filing a licensure application.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Celltrion Launches STEQEYMA (Ustekinumab) In Germany And The Netherlands

    As we previously reported, this August the European Commission granted approval for Celltrion's STELARA biosimilar, STEQEYMA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Showing 381–400 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics